Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Lexicon Pharmaceuticals's EV/EBITDA was 14.2× on Oct 29, 2021, against 1.6× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2021 | Oct 29, 2021 | 14.2× | +11.2 |
| 2020 | Oct 30, 2020 | 3.0× | +0.8 |
| 2019 | Dec 31, 2019 | 2.2× | −458.9 |
| 2016 | Apr 29, 2016 | 461.1× | – |
See a number that looks wrong?